Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Relief Therapeutics Holding's Enterprise Value is CHF27.18 Mil.
Relief Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was CHF-19.76 Mil. Therefore, Relief Therapeutics Holding's EV-to-EBIT ratio for today is -1.38.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Relief Therapeutics Holding (XSWX:RLF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Relief Therapeutics Holding's EV-to-EBIT for today is
Relief Therapeutics Holding's current Enterprise Value is CHF27.18 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was CHF-19.76 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Relief Therapeutics Holding's EV-to-EBITDA for today is:
Relief Therapeutics Holding's current Enterprise Value is CHF27.18 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was CHF-17.89 Mil.
Relief Therapeutics Holding's current Enterprise Value is CHF27.18 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's Revenue for the trailing twelve months (TTM) ended in Jun. 2025 was CHF4.05 Mil.
Relief Therapeutics Holding's current Enterprise Value is CHF27.18 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was CHF-3.51 Mil.
Relief Therapeutics Holding's current Enterprise Value is CHF27.18 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was CHF-3.61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding Enterprise Value Related Terms
Relief Therapeutics Holding Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding Enterprise Value Chart
XSWX:RLF vs KTTA, OSRH, LIMN: Enterprise Value Comparison
For the Biotechnology subindustry, Relief Therapeutics Holding's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's Enterprise Value falls into.
Relief Therapeutics Holding Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of CHF27.18 Mil mean?
Relief Therapeutics Holding (XSWX:RLF) has a Enterprise Value of CHF27.18 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's Enterprise Value too high?
Relief Therapeutics Holding's current Enterprise Value is CHF27.18 Mil. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Enterprise Value compare to KTTA and OSRH?
Relief Therapeutics Holding's Enterprise Value of CHF27.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current Enterprise Value is CHF27.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Enterprise Value of CHF27.18 Mil. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Enterprise Value is CHF27.18 Mil. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Enterprise Value is CHF27.18 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
Enterprise Value: CHF27.18 Mil
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
